Yesterday, Brad Loncar, founder of BiotechTV, stopped by our office outside Copenhagen to talk to our CEO, Adam Steensberg,. They discussed different approaches to treating obesity and the R&D work that we are doing here at Zealand. Check out the clip below or watch the full video here: https://lnkd.in/eHR9H2Tj
𝐅𝐫𝐨𝐦 𝐂𝐨𝐩𝐞𝐧𝐡𝐚𝐠𝐞𝐧: A deep-dive discussion on obesity drug development with Zealand Pharma's CEO Adam Steensberg, MD, MBA. He highlights Zealand’s three different approaches to obesity: glucagon/GLP-1, GLP-1/GLP-2, and an amylin analog. Plus, he shares his thoughts on tolerability, compliance, the development of oral GLP’s, business development, and more. Full video: https://lnkd.in/eHR9H2Tj BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent